可手术肺癌分子残留病灶检测临床应用专家共识(2026版)
Expert Consensus on Clinical Application of Molecular Residual Disease Detection in Resectable Lung Cancer(2026 Edition)
摘要
Abstract
Detection of molecular residual disease(MRD)based on circulating tumor DNA holds signif-icant application value for prognostic assessment and recurrence monitoring in resectable lung cancer.However,current practices lack standardized guidelines regarding core aspects such as target populations,technical ap-proaches,timing of monitoring,and adaptive treatment strategies.To address this,the Chinese Thoracic Oncol-ogy Group(CTONG)YOUNG established a"Working Group on Expert Consensus for Molecular Residual Disease in Resectable Lung Cancer".Based on a systematic review of the latest international advancements and objective evidence-based medical data,the group formulated the Expert Consensus on Clinical Application of Molecular Residual Disease Detection in Resectable Lung Cancer(2026 Edition).This consensus focuses on a systematic and in-depth discussion of key issues,including the selection of target populations for MRD detec-tion,optimization of technical detection pathways,determination of perioperative and postoperative longitudinal follow-up time points,and the clinical value of MRD status in guiding escalation or de-escalation strategies for both treatment-naïve patients and those receiving neoadjuvant therapy.In addition,the consensus specifies the essential components for standardizing MRD detection reports.The aim is to provide an objective scientific basis and decision-making reference for thoracic surgeons and oncologists in clinical practice,thereby advancing the field of resectable lung cancer toward a new era of individualized precision management.关键词
可手术肺癌/循环肿瘤DNA/分子残留病灶/适应性治疗Key words
resectable lung cancer/circulating tumor DNA/molecular residual disease/adaptive therapy分类
医药卫生引用本文复制引用
中国胸部肿瘤研究协作组青年委员会,陈克终..可手术肺癌分子残留病灶检测临床应用专家共识(2026版)[J].协和医学杂志,2026,17(3):617-625,9.基金项目
四大慢病重大专项(2023ZD0501900,2023ZD0501902) （2023ZD0501900,2023ZD0501902）
国家自然科学基金(82525052,82450111,82388102,82373416) （82525052,82450111,82388102,82373416）
中国医学科学院医学与健康科技创新工程(2021 RU002,2021-I2M-5-002) （2021 RU002,2021-I2M-5-002）
研究型病房卓越临床研究计划项目(BRWEP2024W034080200) （BRWEP2024W034080200）
北京市自然科学基金(Z240013) （Z240013）
雄安新区科技创新专项(2023XAGG0071) （2023XAGG0071）
北京大学临床科学家培养计划(BMU2025PYJH001) （BMU2025PYJH001）
北京大学人民医院科研发展基金(RZG2024-02) Noncommunicable Chronic Diseases-National Science and Technology Major Project(2023ZD0501900,2023ZD0501902) （RZG2024-02）
National Natural Science Foundation of China(82525052,82450111,82388102,82373416) （82525052,82450111,82388102,82373416）
Chinese Academy of Medical Sciences(2021RU002,2021-I2M-5-002) （2021RU002,2021-I2M-5-002）
Beijing Research Ward Excellence Program(BRWEP2024W034080200) （BRWEP2024W034080200）
Beijing Natural Science Foundation(Z240013) （Z240013）
Science,Technology&Innovation Project of Xiongan New Area(2023XAGG0071) （2023XAGG0071）
Peking University Clinical Scientist Training Program,supported by"the Fundamental Research Funds for the Central Universities"(BMU2025PYJH001) （BMU2025PYJH001）
Peking University People's Hospital Research and Development Funds(RZG2024-02) （RZG2024-02）
